# ATC code M

> Mediated Wiki article. Canonical URL: https://mediated.wiki/source/ATC_code_M
> Markdown URL: https://mediated.wiki/source/ATC_code_M.md
> Source: https://en.wikipedia.org/wiki/ATC_code_M
> Source revision: 1266915741
> License: Creative Commons Attribution-ShareAlike 4.0 International (https://creativecommons.org/licenses/by-sa/4.0/)

Pharmaceutical drug classification

ATC code M: Musculo-skeletal system M01 Anti-inflammatory and antirheumatic products M02 Topical products for joint and muscular pain M03 Muscle relaxants M04 Antigout preparations M05 Drugs for treatment of bone diseases M09 Other drugs for disorders of the musculo-skeletal system Other ATC codes A B C D G H QI J L M N P R S V

**ATC code M** *Musculo-skeletal system* is a section of the [Anatomical Therapeutic Chemical Classification System](/source/Anatomical_Therapeutic_Chemical_Classification_System), a system of alphanumeric codes developed by the [World Health Organization](/source/World_Health_Organization) (WHO) for the classification of [drugs](/source/Pharmaceutical_drug) and other medical products.[1][2][3][4]

Codes for [veterinary](/source/Veterinary) use ([ATCvet codes](/source/ATCvet_code)) can be created by placing the letter Q in front of the human ATC code: for example, **QM**.[5] National versions of the ATC classification may include additional codes not present in this list, which follows the WHO version.

## References

1. **[^](#cite_ref-1)** ["ATC (Anatomical Therapeutic Chemical Classification System) – Synopsis"](https://www.nlm.nih.gov/research/umls/sourcereleasedocs/current/ATC/index.html). *[National Institutes of Health](/source/National_Institutes_of_Health)*. Retrieved 1 February 2020.

1. **[^](#cite_ref-2)** ["Anatomical Therapeutic Chemical (ATC) Classification"](https://www.who.int/tools/atc-ddd-toolkit/atc-classification). *[World Health Organization](/source/World_Health_Organization)*. Retrieved 3 January 2022.

1. **[^](#cite_ref-3)** ["Structure and principles"](https://www.whocc.no/atc/structure_and_principles/). *WHO Collaborating Centre for Drug Statistics Methodology*. 15 February 2018. Retrieved 3 January 2022.

1. **[^](#cite_ref-4)** ["ATC/DDD Index 2022: code M"](http://www.whocc.no/atc_ddd_index/?code=M). *WHO Collaborating Centre for Drug Statistics Methodology*.

1. **[^](#cite_ref-5)** ["ATCvet Index 2022: code QM"](http://www.whocc.no/atcvet/atcvet_index/?code=M). *WHO Collaborating Centre for Drug Statistics Methodology*.

v t e Major chemical drug groups – based upon the Anatomical Therapeutic Chemical Classification System gastrointestinal tract / metabolism (A) stomach acid Antacids H2 antagonists Proton-pump inhibitors Antiemetics Laxatives Antidiarrhoeals / Antipropulsives Anti-obesity drugs Diabetes medication Vitamins Dietary minerals blood and blood forming organs (B) Antithrombotics Antiplatelets Anticoagulants Thrombolytics / fibrinolytics Antihemorrhagics Platelets Coagulants Antifibrinolytics cardiovascular system (C) cardiac therapy / antianginals Cardiac glycosides Antiarrhythmics Cardiac stimulants Antihypertensives Diuretics Vasodilators Beta blockers Calcium channel blockers renin–angiotensin system ACE inhibitors Angiotensin II receptor antagonists Renin inhibitors Antihyperlipidemics Statins Fibrates Bile acid sequestrants skin (D) Emollients Cicatrizants Antipruritics Antipsoriatics Medicated dressings genitourinary system (G) Hormonal contraception Fertility agents Selective estrogen receptor modulators Sex hormones endocrine system (H) Hypothalamic–pituitary hormones Corticosteroids Glucocorticoids Mineralocorticoids Sex hormones Thyroid hormones / Antithyroid agents infections and infestations (J, P, QI) Antimicrobials: Antibacterials (Antimycobacterials) Antifungals Antivirals Antiparasitics Antiprotozoals Anthelmintics Ectoparasiticides Intravenous immunoglobulin Vaccines malignant disease (L01–L02) Anticancer agents Antimetabolites Alkylating Spindle poisons Antineoplastic Topoisomerase inhibitors immune disease (L03–L04) Immunomodulators Immunostimulants Immunosuppressants muscles, bones, and joints (M) Anabolic steroids Anti-inflammatories Non-steroidal anti-inflammatory drugs Antirheumatics Corticosteroids Muscle relaxants Bisphosphonates brain and nervous system (N) Analgesics Anesthetics General Local Anorectics Anti-ADHD agents Antiaddictives Anticonvulsants Antidementia agents Antidepressants Antimigraine agents Antiparkinson agents Antipsychotics Anxiolytics Aphrodisiacs Depressants Entactogens Entheogens Euphoriants Hallucinogens Psychedelics Dissociatives Deliriants Hypnotics / Sedatives Mood stabilizers Motivation-enhancing drug Neuroprotectives Nootropics Neurotoxins Orexigenics Serenics Stimulants Wakefulness-promoting agents respiratory system (R) Decongestants Bronchodilators Cough medicines H1 antagonists sensory organs (S) Ophthalmologicals Otologicals other ATC (V) Antidotes Contrast media Radiopharmaceuticals Dressings Senotherapeutics Drugs Pharmacological classification systems ATC codes Medicine portal

v t e Nonsteroidal anti-inflammatory drugs (NSAIDs) (primarily M01A and M02A, also N02BA) pyrazolones / pyrazolidines Aminophenazone Ampyrone Azapropazone Clofezone Difenamizole Famprofazone Feprazone Kebuzone Metamizole Mofebutazone Morazone Nifenazone Oxyphenbutazone Phenazone Phenylbutazone Propyphenazone Sulfinpyrazone Suxibuzone‡ salicylates Aspirin (acetylsalicylic acid)# Aloxiprin Benorylate Carbasalate calcium Diflunisal Dipyrocetyl Ethenzamide Guacetisal Magnesium salicylate Methyl salicylate Salsalate Salicin Salicylamide Salicylic acid (salicylate) Sodium salicylate acetic acid derivatives and related substances Aceclofenac Acemetacin Alclofenac Amfenac Bendazac Bromfenac Bufexamac Bumadizone Diclofenac Difenpiramide Etodolac Felbinac Fenclozic acid Fentiazac Indometacin Indometacin farnesil Isoxepac Ketorolac Lonazolac Mofezolac Oxametacin Prodolic acid Proglumetacin Sulindac Tiopinac Tolmetin Zomepirac† oxicams Ampiroxicam Droxicam Isoxicam Lornoxicam Meloxicam Piroxicam Pivoxicam Tenoxicam propionic acid derivatives (profens) Alminoprofen Benoxaprofen† Carprofen‡ Dexibuprofen Dexketoprofen Fenbufen Fenoprofen Flunoxaprofen Flurbiprofen Ibuprofen# Ibuproxam Indoprofen† Ketoprofen Loxoprofen Miroprofen Naproxen Oxaprozin Pelubiprofen Piketoprofen Pirprofen Suprofen Tarenflurbil Tepoxalin‡ Tiaprofenic acid Vedaprofen‡ Zaltoprofen COX-inhibiting nitric oxide donator: Naproxcinod n-arylanthranilic acids (fenamates) Azapropazone Clonixin Etofenamate Floctafenine Flufenamic acid Flunixin Flutiazin Glafenine† Meclofenamic acid Mefenamic acid Morniflumate Niflumic acid Tolfenamic acid COX-2 inhibitors (coxibs) Apricoxib Celecoxib (+tramadol) Cimicoxib‡ Deracoxib‡ Etoricoxib Firocoxib‡ Lumiracoxib† Mavacoxib‡ Parecoxib Robenacoxib‡ Rofecoxib† Valdecoxib† other Aminopropionitrile Benzydamine Chondroitin sulfate Diacerein Fluproquazone Glucosamine Glycosaminoglycan Grapiprant‡ Hyperforin Nabumetone Nimesulide Oxaceprol Proquazone Superoxide dismutase / orgotein Tenidap NSAID combinations Ibuprofen/famotidine Ibuprofen/hydrocodone Ibuprofen/oxycodone Ibuprofen/paracetamol Meloxicam/bupivacaine Meloxicam/rizatriptan Naproxen/diphenhydramine Naproxen/esomeprazole Key: underline indicates initially developed first-in-class compound of specific group; #WHO-Essential Medicines; †withdrawn drugs; ‡veterinary use. category commons portal

v t e Specific antirheumatic products / DMARDs (M01C) Quinolines Oxycinchophen Gold preparations Sodium aurothiomalate Sodium aurothiosulfate Auranofin Aurothioglucose Aurotioprol Other Penicillamine #/Bucillamine Chloroquine #/Hydroxychloroquine Leflunomide Sulfasalazine # antifolate (Methotrexate #) thiopurine (Azathioprine) # #WHO-EM ‡Withdrawn from market Clinical trials: †Phase III §Never to phase III

v t e Topical products for joint and muscular pain (M02) Anti-inflammatory preparations, non-steroids Pyrazolidines Clofezone Mofebutazone Oxyphenbutazone Phenylbutazone Acetic acid derivatives Diclofenac Fentiazac Tolmetin Other Bendazac Benzydamine Bufexamac Etofenamate Felbinac Feprazone Flurbiprofen Ibuprofen Indometacin Ketoprofen Meclofenamic acid Naproxen Nifenazone Niflumic acid Piketoprofen Piroxicam Suxibuzone Capsaicin derivatives Zucapsaicin Other Dimethyl sulfoxide Idrocilamide Tolazoline

v t e Skeletal muscle relaxants (M03) Peripherally acting (primarily antinicotinic, NMJ block) Non-depolarizing Curare alkaloids Alcuronium Dimethyltubocurarine Tubocurarine 4° ammonium agents ultra-short duration: Gantacurium short duration: Rapacuronium Mivacurium Chandonium intermediate duration: Atracurium Cisatracurium Fazadinium Rocuronium Vecuronium long duration: Doxacurium Dimethyltubocurarine Pancuronium Pipecuronium Laudexium Gallamine unsorted: Hexafluronium (Hexafluorenium) Depolarizing Choline derivatives: Suxamethonium (Succinylcholine) Polyalkylene derivatives: Hexamethonium ACh release inhibitors Botulinum toxin Centrally acting Carbamic acid esters Carisoprodol Cyclarbamate Difebarbamate Febarbamate Meprobamate Phenprobamate Styramate Tybamate Benzodiazepines Bromazepam Diazepam Clonazepam Flunitrazepam Lorazepam Nitrazepam Temazepam Tetrazepam Nonbenzodiazepines Eszopiclone Thienodiazepines Etizolam Quinazolines Methaqualone Anticholinergics (Antimuscarinics) Cyclobenzaprine Orphenadrine Other Arbaclofen placarbil Baclofen Chlormezanone Chlorphenesin Chlorzoxazone Eperisone Fenyramidol Flopropione Gabapentin GHB Inaperisone Lanperisone Mephenesin Mephenoxalone Metaxalone Methocarbamol Phenibut Pregabalin Pridinol Promoxolane Quinine Silperisone Thiocolchicoside Tizanidine Tolperisone Zoxazolamine Directly acting Dantrolene

v t e Drugs used for gout (M04) Uricosurics primary Probenecid Sulfinpyrazone Benzbromarone Isobromindione Lesinurad‡ Dotinurad secondary Amlodipine Atorvastatin Fenofibrate Guaifenesin Losartan Xanthine oxidase inhibitors purine analogues Allopurinol# Oxypurinol Tisopurine other Febuxostat Inositols (Phytic acid Myo-inositol) Topiroxostat Mitotic inhibitors Colchicine Other Cinchophen NSAIDs except aspirin Sevelamer Urate oxidase (Rasburicase Pegloticase) #WHO-EM ‡Withdrawn from market Clinical trials: †Phase III §Never to phase III

v t e Drugs for treatment of bone diseases (M05) Bisphosphonates Nitrogenous Alendronic acid Ibandronic acid Incadronic acid Minodronic acid Neridronic acid Pamidronic acid Risedronic acid Zoledronic acid Non-nitrogenous Etidronic acid Clodronic acid Tiludronic acid Bone morphogenetic proteins Dibotermin alfa Eptotermin alfa Other Resorption inhibitor Ipriflavone Aluminium chlorohydrate Dual action bone agent Strontium ranelate RANKL inhibitor Denosumab Sclerostin inhibitor Romosozumab Cathepsin K inhibitor Odanacatib Parathyroid hormone-related protein analogues Abaloparatide Teriparatide Calcitonin Calcium Vitamin D

v t e Other drugs for disorders of the musculo-skeletal system (M09) Quinine and derivatives Hydroquinine Enzymes Bromelains Chymopapain Collagenase clostridium histolyticum Trypsin Gene therapies Delandistrogene moxeparvovec Onasemnogene abeparvovec Antisense oligonucleotides Casimersen Drisapersen† Eteplirsen Golodirsen Nusinersen Viltolarsen Glucocorticoids Deflazacort Vamorolone Histone deacetylase inhibitors Givinostat Other Aceneuramic acid Ataluren Branaplam Chondrocytes Hyaluronic acid Palovarotene Risdiplam #WHO-EM ‡Withdrawn from market Clinical trials: †Phase III §Never to phase III

This pharmacology-related article is a stub. You can help Wikipedia by adding missing information.

- [v](https://en.wikipedia.org/wiki/Template:Pharma-stub)
- [t](/source/Template_talk%3APharma-stub)
- [e](https://en.wikipedia.org/wiki/Special:EditPage/Template:Pharma-stub)

---
Adapted from the Wikipedia article [ATC code M](https://en.wikipedia.org/wiki/ATC_code_M) by Wikipedia contributors ([contributor history](https://en.wikipedia.org/wiki/ATC_code_M?action=history)). Available under [Creative Commons Attribution-ShareAlike 4.0 International](https://creativecommons.org/licenses/by-sa/4.0/). Changes may have been made.